Changes in Hong Kong stocks | Yingpai Pharmaceutical-B (07630) rose nearly 10% to grant exclusive rights to the cancer treatment product Senapali or receive up to more than 400 million euros and royalties

The Zhitong Finance App learned that Yingpai Pharmaceutical-B (07630) rose nearly 10%. As of press release, it had risen 9.72% to HK$12.64, with a turnover of HK$681,800.

According to news, on July 30, Yingpai Pharmaceutical announced that it had reached an exclusive cooperation with Pharmanovia, a global pharmaceutical company, to grant Pharmanovia the exclusive production, development and commercialization rights to use Senapa to maintain monotherapy for advanced epithelial high-grade ovarian cancer, fallopian tube cancer, and primary peritoneal cancer in Europe, the Middle East, North Africa, Australia and New Zealand. Yingpai Pharmaceuticals is expected to receive a total of up to 423.5 million euros in payments, including down payment, recent registration milestone payments and commercialization milestone payments that have reached the corresponding sales threshold, and tiered royalties based on up to 20% of the product's net sales (% in the middle 20 digits).

Under the license agreement relating to this exclusive cooperation, Yingpai Pharmaceutical granted Pharmanovia the exclusive production, development and commercialization rights to maintain monotherapy for advanced epithelial high-grade ovarian cancer, fallopian tube cancer and primary peritoneal cancer in 66 countries (including all 27 EU member states, as well as the United Kingdom, Norway, Iceland, Switzerland, Liechtenstein, Australia, New Zealand, and countries in the Middle East and North Africa region).